TP53 and cancer: The presence of YARA further decreased the IC50 values compared to piplartine in solution, and a reduction of 2.6-fold (4.0 μM) and 4.1-fold (2.3 μM) in the drug IC50 was observed in MCF-7 and T47-D cells, respectively, suggesting that the targeting of MK2 is a useful strategy to enhance killing of p53-defective cancer cells like T47-D [39,65,66].